Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16159241 | 0.88 | ROCK2 (0.43) | ROCK2CYP11B1CYP11B2MAPK8PDK2 | |
| SCHEMBL16159086 | 0.82 | KMT2A (0.40) | CYP11B1CYP11B2MAPK8PDK2MEN1 | |
| SCHEMBL16159855 | 0.82 | MAPK8 (0.39) | CYP11B1CYP11B2MAPK8PDK2MEN1 | |
| SCHEMBL16159252 | 0.82 | ROCK2 (0.36) | ROCK2CYP11B1CYP11B2MAPK8PDK2 | |
| SCHEMBL16159243 | 0.82 | AR (0.37) | PIK3R2IMPDH2 | |
| SCHEMBL16159613 | 0.80 | IRAK4 (0.33) | MAPK8PIK3R2 | |
| SCHEMBL16159705 | 0.80 | CYP11B1 (0.36) | CYP11B1CYP11B2MAPK8PDK2MEN1 | |
| SCHEMBL16159264 | 0.79 | CYP11B1 (0.42) | ROCK2CYP11B1CYP11B2PDK2PIK3R2 | |
| SCHEMBL17116473 | 0.78 | IRAK4 (0.35) | ROCK2CYP11B1CYP11B2MAP4K4 | |
| SCHEMBL20410194 | 0.78 | SMN1; SMN2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| WO-2014163173-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC株式会社 (JP) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | HVCN1, VDAC1, SLC26A3 | ROCK2 3962/4885CYP11B1 312/4885CYP11B2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.